Indication
Transplant Failure
4 clinical trials
4 products
4 drugs
Clinical trial
Factors Affecting the Tacrolimus Blood Concentration and Its Impact on Transplant-related Outcomes in Pediatric HSCT Recipients: a Single-center Retrospective StudyStatus: Recruiting, Estimated PCD: 2024-09-29
Product
TACClinical trial
Impact of SGLT2 Inhibitors on Cardioprotection in Patients Undergoing Heart TransplantationStatus: , Estimated PCD: 2025-02-01
Drug
SGLT2iClinical trial
Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols Accompanied by Maintenance Therapy With Prograf® and Myfortic®Status: Completed, Estimated PCD: 2010-05-01
Drug
alemtuzumabProduct
DaclizumabProduct
ThymoglobulinClinical trial
Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPAStatus: Completed, Estimated PCD: 2020-09-01
Product
belataceptDrug
VarlilumabDrug
MPA